Fatores associados ao ganho de peso em pacientes com câncer de mama em hormonioterapia

Hormone therapy is a method consisting of the use of hormone inhibitors for the treatment of receptor-positive breast cancer, estrogen and progesterone receptors. The types of hormone therapy used are selective estrogen receptor modulators (SERM) and aromatase inhibitors (IA). It is noteworthy that hormone therapy can cause increased appetite, water retention, and progressive weight gain. The objective of this staudy is to evaluate the nutritional status of women with breast cancer on hormone therapy at a private clinic in the Federal District. Methods: Across-sectional, analytical and descriptive study, approved by the Research Ethics Committee, was conducted from September to October 2018, in a private clinic in the Federal District, involving patients diagnosed with breast cancer using hormone therapy, female, aged ≥ 18 years. Anthropometric parameters were evaluated by bioimpedance, arm circumference, calf, and tricipital and bicipital folds. As a method of assessment of nutritional status and symptomatology was applied the global subjective assessment produced by the patient (ASG-PPP). Results: The sample consisted of 18 women over 35 years old, who were pre- and postmenopausal in the post-treatment stage of the disease, with an average BMI of 28 kg/m2. Most women (74%, n = 13) were overweight and obese, in which 89% of participants had weight gain since the beginning of treatment. An association of weight change with SGA-PPP was also analyzed, and only 6% of the interviewed population was at risk. Conclusion: Given the data presented, it cannot be stated that the results obtained are solely related to the use of adjuvant therapy drugs